MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib

The third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI–treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its un...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiyama, Akihiro, Takeuchi, Shinji, Adachi, Yuta, Otani, Sakiko, Tanimoto, Azusa, Sasaki, Motoko, Matsumoto, Shingo, Goto, Koichi, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Drug Discovery and Delivery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540985/
https://www.ncbi.nlm.nih.gov/pubmed/32735723
http://dx.doi.org/10.1111/cas.14593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540985/
https://www.ncbi.nlm.nih.gov/pubmed/32735723
http://dx.doi.org/10.1111/cas.14593

Ejemplares similares